Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;30 Suppl 1(Suppl 1):18-22.
doi: 10.1111/exd.14339.

Anti-COVID-19 measurements for hidradenitis suppurativa patients

Evangelos J Giamarellos-Bourboulis  1   2 , Vincenzo Bettoli  1   3 , Gregor B E Jemec  1   4   5 , Veronique Del Marmol  1   6 , Angelo V Marzano  1   7   8 , Errol P Prens  1   9   10 , Thrasyvoulos Tzellos  1   11 , Christos C Zouboulis  1   12
Affiliations

Anti-COVID-19 measurements for hidradenitis suppurativa patients

Evangelos J Giamarellos-Bourboulis et al. Exp Dermatol. 2021 Jun.

Abstract

The reported incidence of COVID-19 among cohorts of patients with inflammatory bowel and skin diseases under treatment with biologicals is low. Treatment may further modify disease severity as some biological modifiers, such as anakinra, are also proposed for the management of COVID-19 patients potentially providing HS patients with an advantage. The above preliminary evidence suggests that hidradenitis suppurativa (HS) does probably not provide an increased susceptibility for COVID-19 and that any susceptibility is unlikely to be modified negatively by treatment with biologicals. On the occasion of its 10th International Conference, experts of the European Hidradenitis Suppurativa Foundation e.V. have prepared a consensus statement regarding anti-COVID-19 measurements for HS patients. Based on the available knowledge, patients with HS may be vaccinated against SARS-CoV2 and patients affected by metabolic syndrome constitute a high-risk group for COVID-19 and should be vaccinated at the earliest convenient point in time. HS patients on treatment with adalimumab can be vaccinated with non-living virus anti-SARS-CoV2 vaccines. A possible suboptimal effect of the vaccine may be suspected but might not be expected universally. The management of the biological treatment in HS patients is at the discretion of the dermatologist / responsible physician.

Keywords: COVID-19; SARS-CoV2; hidradenitis suppurativa; vaccine.

PubMed Disclaimer

Conflict of interest statement

EJG‐B, VB, GBEJ, VdM, AVM, EPP, TT, CCZ declare that none of the mentioned conflicts of interest had any influence to this manuscript. EJG‐B has received honoraria from Abbott, Angelini, bioMérieux, InflaRx, MSD and XBiotech; independent educational grants from AbbVie, Abbott, Astellas, AxisShield, bioMérieux, InflaRx, Thermo Fisher Brahms and XBiotech; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie‐Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens) and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). GBEJ has received honoraria from AbbVie, Chemocentryx, Coloplast, Incyte, Inflarx, Kymera Therapeutics, LEO, Novartis and UCB for participation on advisory boards, and grants from Abbvie, Astra‐Zeneca, Inflarx, Janssen‐Cilag, LEO, Novartis, Regeneron and Sanofi for participation as an investigator, and received speaker honoraria from AbbVie, Boehringer‐Ingelheim, Galderma and Novartis. He has also received unrestricted departmental grants from LEO and Novartis. VdM has received honoraria for advisory board participation from BMS, Leo Pharma, Sanofi. EPP received honoraria from AbbVie, Amgen, Celgene, Galderma, Janssen‐Cilag, Novartis and Pfizer for participation as a speaker and serving on advisory boards and investigator‐initiated grants (paid to the Erasmus MC) from AbbVie, AstraZeneca, Janssen‐Cilag and Pfizer. TT reports fees from AbbVie, UCB and Sanofi (consultancy, speaker honorarium). CCZ has received thematically relevant honoraria from Incyte, Inflarx, Janssen‐Cilag, Novartis, Regeneron and UCB as advisor. His departments have received grants from AbbVie, AOTI, Astra Zeneca, Galderma, Inflarx, Naos‐Bioderma, Novartis, PPM and UCB for his participation as clinical investigator. AVM declares no conflict of interest.

Comment in

References

    1. Koutsakos M, Rowntree LC, Hensen L, et al. Integrated immune dynamics define correlates of COVID‐19 severity and antibody responses. Cell Rep Med 2021; 2: 100208. - PMC - PubMed
    1. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS‐CoV‐2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021; 20:102792. - PMC - PubMed
    1. Welzel T, Samba SD, Klein R, van den Anker JN, Kuemmerle‐Deschner JB. COVID‐19 in autoinflammatory diseases with immunosuppressive treatment. J Clin Med. 2021;10:605. - PMC - PubMed
    1. Lakota K, Perdan‐Pirkmajer K, Hočevar A, et al. COVID‐19 in association with development, course, and treatment of systemic autoimmune rheumatic diseases. Front Immunol. 2021;11:611318. - PMC - PubMed
    1. Ralf Paus L, Kurzen H, Kurokawa I, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008;17:455‐472. - PubMed

Publication types

MeSH terms

Substances